Insurance companies only profit from prevention when they can prevent something they'd been paid to insure against beforehand. They may be forced to employ prevention to offer competitive insurance deals, but that makes them interested only in individual prevention for their customers. From a revenue perspective they depend on the prevalence of sickness.
I'm not saying that everybody in an insurance outfit has their priorities consciously aligned like that. But we shouldn't expect advice from an insurance to be good for our health. Sometimes they might prefer if we die fast. Or stay in therapy and opt for the extra-care package.
Additionally, suggesting solutions that don't have any revenue attached to them is doubleplusungood for the HN denizens for whom the only yardstick of progress is Tres Commas Tequila.
Gilead, a successful biotech/pharma, among others, noticed that with rising obesity,there were a number of dieases increasing in prevalence (NASH is an example). They chose to try to develop a drug for NASH, spent billions to come up with promising leads, then they failed in stage 2 or 3 (last steps before approval).
When companies spent billions on drugs, and they fail, that cost is eaten, the company doesn't make much less profit, it just factors those costs into other drugs, mainly in countries where they expect people can afford higher drug prices.
I don't blame biotech/pharma (who are driven by profit motive) for chasing expensive drugs that don't address the underlying problem, but if the equivalent amount of money had been instead spent on simple methods to reduce obesity. Who is going to spend that kind of money on general health improvements without a profit motive (other than, say, our government)?
All the above is a great simplification, but it's an example of how we got into the situation we are in. We tend to go for high-tech patches of problems rather than root causing, and it seems tied to the profit motives of companies. Ultimately I think only the government is capable of addressing structural issues like this, either by funding the research and orgs who deal with root causes, or by making laws that incentive good behavior in biotech/pharma.